Marksans Pharma Limited
Quick Take
- • Trading at 28.1× trailing earnings (22.8× forward)
- • Strong ROE at 17.1%
- • Low leverage (D/E 0.11)
- • Modest dividend yield of 0.28%
- • Operating margin 22.4% · Net margin 16.3%
- • Profit growth +169.00% YoY · Beta 1.15
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 841 | -1.75% | +35.65% |
| Operating Profit | 238 | +3.03% | +124.53% |
| Net Profit | 157 | +6.08% | +170.69% |
| EPS (₹) | 3.47 | +6.12% | +168.99% |
Shareholding Pattern
| Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FIIs▲0.71 | 21.31% | 21.96% | 22.20% | 19.88% | 16.92% | 16.74% | 16.76% | 17.47% |
| DIIs▼0.38 | 4.10% | 4.30% | 4.56% | 5.50% | 5.28% | 5.91% | 6.57% | 6.19% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public▼0.32 | 30.71% | 29.87% | 29.37% | 30.75% | 33.93% | 33.47% | 32.79% | 32.47% |
| No. of Shareholders | 2,48,845 | 2,59,813 | 2,57,273 | 2,56,221 | 2,65,788 | 2,55,153 | 2,46,279 | 2,46,635 |
* 1. The Company has 61 outstanding FCCBs held by one bond holder. 81,314 Equity Shares will be issued against these FCCBs in case the bond holder exercises the conversion right. 2. The Company has granted, on 24th September 2025, 4,00,000 and on 25th May 2026 3,00,000 employee stock options to certain identified eligible employees exercisable for acquiring equal number of Equity Shares of face value of Re. 1 each fully paid-up under Marksans Employees Stock Option Scheme 2024. 3. The NRI holding specified under B (4) (i) as total 6954411 (1.53%) is bifurcated as 4242107 (0.94%) share on Rep
| Date | Party | Type | Side | Qty | Price |
|---|---|---|---|---|---|
| 12 Aug 26 | Microcurves Trading Private Limited | Bulk deal | SELL | 43,49,697 | ₹313.40 |
| 12 Aug 26 | Microcurves Trading Private Limited | Bulk deal | BUY | 43,49,697 | ₹313.24 |
About the company
From latest AR & concallMarksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
